ViaDerma (VDRM) AI Stock Analysis

• Market Cap: $863.60K
• Dividend Yield: N/A
• Average Volume (3M): 581.10K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.15
• Revenue Growth: 2.52%
• EPS Growth: -100.00%
• Country: US
• Employees: 75
• Sector: Healthcare
• Sector Strength: 43
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.00
• Shares Outstanding: 1,233,713,100
• 10 Day Avg. Volume: 428,867
• 30 Day Avg. Volume: 581,103
• PEG Ratio: 0.31
• Price to Book (P/B): -145.25
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -41.38
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: ―

ViaDerma shows strong revenue growth and high gross profit margins, but faces significant challenges including declining profitability, high leverage, and a lack of detailed cash flow data. Technical indicators are insufficient for thorough analysis, and valuation metrics suggest the stock is overvalued. Earnings call data provides limited additional insights.

ViaDerma Business Overview & Revenue Model

Company Description

ViaDerma, Inc. operates as a specialty pharmaceutical company in the United States. It focuses on developing and marketing pharmaceutical products, as well as licensing its technology to companies in the pharmaceutical industry in various therapeutic areas. The company's lead product is Vitastem, a tetracycline-based topical antibiotic used for cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries. It is also developing products in various fields of use, including topical antibiotics, toenail antifungal drugs, diabetic amputations, global acne, psoriasis, and eczema, as well as burns, anti-aging/wrinkle remover creams, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management. The company was formerly known as Décor Products International, Inc. and changed its name to ViaDerma, Inc. in May 2014. ViaDerma, Inc. was incorporated in 2007 and is headquartered in Marina Del Rey, California.

How the Company Makes Money

ViaDerma generates revenue through the commercialization and sales of its proprietary topical products, particularly Vitastem. The company earns money by directly selling its products to healthcare providers, pharmacies, and distributors. Additionally, ViaDerma may engage in licensing agreements or partnerships with other pharmaceutical companies to expand the reach and application of its drug delivery technology, further contributing to its revenue streams.

ViaDerma Financial Statement Overview

Summary

ViaDerma exhibits strong revenue growth and gross profit margins, but faces challenges with declining net profit margins and high leverage. The lack of detailed cash flow data adds uncertainty.

Income Statement

ViaDerma has shown a consistent increase in total revenue over the years, with a significant jump from 2020 to 2023. The gross profit margin is extremely high at approximately 99%, indicating efficient cost management related to revenue. However, the net profit margin has dramatically decreased from 2022 to 2023, suggesting rising expenses or other financial burdens. The EBIT and EBITDA margins have remained positive, but their decline suggests decreased operational profitability.

Balance Sheet

The company's debt-to-equity ratio highlights a high level of leverage, which poses a financial risk. Liabilities have consistently outweighed assets, but stockholders' equity has turned positive in 2023, indicative of improved equity standing. Return on equity (ROE) is positive but may not fully reflect the company's financial health due to prior negative equity. The equity ratio remains low, indicating potential solvency issues.

Cash Flow

ViaDerma's cash flow statements lack crucial data on operating and free cash flows, hindering comprehensive cash flow analysis. The absence of free cash flow growth rate and operating cash flow to net income ratio limits the evaluation of cash flow efficiency and sustainability.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
450.74K	600.50K	540.65K	514.01K	11.47K	10.39K
	Gross Profit
450.60K	600.30K	540.45K	511.33K	10.83K	9.86K
	EBIT
-130.75K	185.27K	245.19K	328.12K	-70.67K	-337.76K
	EBITDA
-130.61K	80.71K	689.84K	328.32K	-70.47K	-338.07K
	Net Income Common Stockholders
-194.16K	4.10K	590.67K	-994.18K	-431.67K	-599.27K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
10.24K	10.24K	10.07K	11.56K	10.13K	9.90K
	Total Assets
1.28M	1.28M	713.98K	275.02K	123.03K	69.22K
	Total Debt
322.94K	322.94K	415.18K	415.18K	588.60K	769.60K
	Net Debt
312.70K	312.70K	405.11K	403.62K	578.46K	759.70K
	Total Liabilities
1.16M	1.16M	2.56M	2.71M	2.31M	3.07M
	Stockholders Equity
123.15K	123.15K	-1.84M	-2.44M	-2.19M	-3.00M
Cash Flow		Free Cash Flow
-507.18K	―	―	―	-8.77K	-15.12K
	Operating Cash Flow
-507.18K	―	―	―	-8.77K	-15.12K
	Investing Cash Flow
0.00	0.00	0.00	0.00	0.00	0.00
	Financing Cash Flow
1.54M	0.00	0.00	0.00	9.00K	15.00K

ViaDerma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AYTU	59 Neutral	$12.53M	―	3.29%	―	-26.17%	―
Sector *	53 Neutral	$5.14B	3.06	-43.57%	2.81%	16.81%	-0.12%
TXMD	47 Neutral	$17.25M	―	-7.72%	―	35.25%	81.05%
DRRX	46 Neutral	$16.89M	―	-203.11%	―	-41.45%	40.69%
VDRM	41 Neutral	$863.60K	―		―	2.52%	-100.00%
KALA	31 Underperform	$26.39M	―	-576.46%	―	―	38.50%
SXTC		$40.60M	0.61	57.63%	―	―	―